Amber Edwards Appointed as CEO of Sinclair Pharma

Sinclair Pharma has announced Amber Edwards as its new Global Chief Executive Officer, effective 1st October 2024. Edwards brings over 25 years of experience in the health and wellness industry, with a strong track record in pharmaceuticals, medical aesthetics, and medical devices. She has held executive roles in both start-ups and large corporations, including her most recent position as Chief Commercial Officer at Alastin Skincare. There, she significantly grew revenue and played a key role in Alastin’s acquisition by Galderma​.

"Amber's extensive experience in both start-ups and large corporations, combined with her customer-centric approach and executional excellence, make her the perfect choice to lead Sinclair," said Chengwei Liu, Chairman, Sinclair "The Board looks forward to working with Amber as she leads Sinclair through the next phase of development and growth."

"I am thrilled to join Sinclair and to work alongside such a talented team to continue delivering innovative solutions for healthcare professionals and consumers in this rapidly growing category" said Ms. Edwards, Global Chief Executive Officer, Sinclair. "With a scientifically differentiated portfolio, encompassing a broad range of products for skin rejuvenation and body contouring, and a clear pathway for additional registrations in the U.S., Sinclair is well positioned to become a global leader in Medical Aesthetics".

As CEO, Edwards will oversee Sinclair’s ongoing expansion into international markets, leveraging her extensive experience in scaling businesses globally. Her appointment signals Sinclair’s commitment to innovation and growth within the aesthetics industry, focusing on providing advanced skin rejuvenation and body contouring solutions. The company, known for its differentiated aesthetics technologies, is aiming for increased market presence across Europe, North America, and Asia, with additional product line expansions on the horizon.